Antiepileptic Medications 03

Topic: Pharmacology

Created on Friday, September 28 2007 by jdmiles

Last modified on Friday, September 28 2007.

 
        A) Levetiracetam
 
        B) Fosphenytoin
 
        C) Phenytoin
 
        D) Ethosuximide
 
        E) Felbamate
 

 

	= Go back to the top of the page.
	= Reload a different version of this question ().
	= Load a random question from the database.
	= Use this question as a template to create a totally NEW question.
	= Enter detailed rating for this question!
	= How users like you have rated this question.

This question was created on September 28, 2007 by jdmiles.
This question was last modified on September 28, 2007.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANSWERS AND EXPLANATIONS

---

A) Levetiracetam

This answer is incorrect.

Levetiracetam is not associated with a high risk of aplastic anemia and hepatotoxicity.  There are no reports of serious side effects with levetiracetam to date.  Drowsiness and dizziness are the more common side effects.  Behavioral problems may occur with some patients.  (See References)

Please log in if you want to rate questions.

 

 

 

 

 

 

 

 

 

---

B) Fosphenytoin

This answer is incorrect.

Fosphenytoin is not associated with a high risk of aplastic anemia and hepatotoxicity.  (See References)

Please log in if you want to rate questions.

 

 

 

 

 

 

 

 

 

---

C) Phenytoin

This answer is incorrect.

Phenytoin is not associated with a high risk of aplastic anemia and hepatotoxicity.  Aplastic anemia may occur as a reaction to phenytoin, but is rare.  A common side effect of phenytoin is gingival hyperplasia.

  (See References)

Please log in if you want to rate questions.

 

 

 

 

 

 

 

 

 

---

D) Ethosuximide

This answer is incorrect.

Ethosuximide is effective in treating uncomplicated absence seizures.  It is not effective in treating motor seizures which can accompany absence seizures.  The most common serious adverse reaction is leukopenia.  Aplastic anemia can occur rarely.  It is not associated with a high risk of hepatotoxicity.  (See References)

Please log in if you want to rate questions.

 

 

 

 

 

 

 

 

 

---

E) Felbamate

This answer is correct.

Felbamate is considered effective as adjunctive therapy in the treatment of Lennox-Gastaut syndrome.  However, it is associated with a relatively high risk for hepatotoxicity and aplastic anemia.

  (See References)

Please log in if you want to rate questions.

 

 

 

 

References:

1. Browne, T.R., & Holmes, G.L. (2004). Handbook of Epilepsy, 3rd Edition. Lippincott Williams & Wilkins, Philadelphia.
2. Leppik, I.E. (2001). Contemporary Diagnosis and Management of the Patient with Epilepsy, 5th Edition. Handbooks in Health Care, Newtown, Pennsylvania.
3. Ilo E. Leppik, . . Handbooks in Health Care Company (ISBN:1931981574)	Advertising:
4. French, J., Smith, M., Faught, E., and Brown, L. (1999). "Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society." Neurology, 52(8) 1540-5. (PMID:10331676)
5. Trescher, W.H., and Lesser, R.P. (2004). The epilepsies. In Bradley, W.G., Daroff, R.B., Fenichel, G.M., and Jankovic, J. (Eds.). Neurology in Clinical Practice, Fourth Edition. Butterworth Heinemann, Philadelphia, pp. 1953-1992.

Please log in if you want to rate questions.

 

FrontalCortex.com -- Neurology Review Questions -- Neurology Boards -- Board Review -- Residency Inservice Training Exam -- RITE Exam Review
pharmacology
Antiepileptic Medications 03
Question ID: 092807072
Question written by J. Douglas Miles, (C) 2006-2009, all rights reserved.
Created: 09/28/2007
Modified: 09/28/2007
Estimated Permutations: 163800